Fulvestrant?Faslodex? 0.25?g | EVER Pharma (Germany) | Price comparison Subtotal: $2.00
Brigatinib Tablets 180?mg – ALK/EGFR TKI for Preclinical Cancer Research
$2.00
Brigatinib Tablets (brand: Alunbrig®), manufactured by Penn Pharmaceutical Services Ltd. (NMPA No.?HJ20220021; Code?86979422000120), are anlotinib analog used as a potent ALK and mutated EGFR tyrosine kinase inhibitor in preclinical cancer research. Supplied as 180?mg tablets, 28 per box. Strictly for laboratory research use?Please consult the staff for other purposes?
描述
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Brigatinib Tablets (Alunbrig®) |
| Strength | 180?mg per tablet |
| Quantity | 28 tablets per box |
| Dosage Form | Oral tablet |
| Approval No. (NMPA) | HJ20220021 |
| Product Code | 86979422000120 |
| Manufacturer | Penn Pharmaceutical Services Ltd (UK) |
| CAS Number | 1197953?54?0 pubmed.ncbi.nlm.nih.gov+15en.wikipedia.org+15ce.mayo.edu+15 |
| Mechanism Class | ALK/EGFR tyrosine kinase inhibitor |
| Intended Use | Laboratory research only — not for clinical use |
Mechanism of Action
Brigatinib is a next-generation, orally active TKI targeting ALK fusion proteins and mutated EGFR, including EGFR C797S, offering high potency and significant intracranial efficacy for ALK-positive cancer models.
en.wikipedia.org
Research & Pharmacology Context
-
Clinically approved in the US and EU for ALK-positive NSCLC based on Phase?3 ALTA?1L trial results.
Brigatinib showed improved progression-free survival and brain metastasis responses versus crizotinib, with dosing beginning at 90?mg/day (7?days) then escalating to 180?mg/day.
-
High CNS penetration makes it ideal for preclinical brain metastases studies.
Research Applications
-
ALK+ NSCLC xenograft models (including brain metastasis studies)
-
EGFR?mutant resistance models, including C797S studies
-
Dose-escalation regimens using 90???180?mg schemes
-
Pharmacokinetic and pharmacodynamics profiling in preclinical animals
Research?Use Only Disclaimer
This product is provided strictly for laboratory research and development use only. Not approved for clinical, diagnostic, therapeutic, or veterinary applications.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Ivodazumab Injection (lvonescimab) – 10?ml per Vial [For Laboratory Research Only]
Ivodazumab (Yidafang®) is a monoclonal antibody developed by Kangfang Pharmaceutical Co., Ltd., approved by China's NMPA (Approval No. S20240020; Drug Code: 86985204000011). Each vial contains 10?ml of the injectable formulation. Strictly for laboratory research use only—not for clinical or human use.
$1.00 -
Aprepitant Capsules (Kangrenping®) – 125?mg [For Laboratory Research Use Only]
Aprepitant Capsules (Kangrenping®), 125?mg ×1 + 80?mg ×2 per box. For laboratory research use only $1.00 -
Palbociclib Capsules (Xipeilai) – 125?mg, 21 Capsules Price comparison
Palbociclib Capsules (Research Grade) in 125?mg strength, 21-count bottle. Supplied by Shanghai Chuannuo Pharmaceutical Co., Ltd. For investigational or research applications only—not for human consumption or therapeutic use.
$2.00 -
Regorafenib Tablets (Reodixin®) – 40?mg
Regorafenib (Reodixin®) is an oral multi-kinase inhibitor targeting angiogenesis, proliferation, metastasis, and tumor immunity. FDA-approved for several advanced solid tumors. Here offered as 40?mg tablets in a 28-count bottle—strictly for laboratory research use only $1.00
评价
目前还没有评价